Painless Gastrointestinal Endoscopy
Conditions
Interventions
Ciprofol group:The initial intravenous dose of Ciprofol is 0.6mg/kg, and the injection time is 30 seconds.
Ciprofol+Sufentanil group:Sufentanil was administered intravenously at 0.1µg/kg, and then 0.4mg/kg Ciprofol was slowly injected 1min later for 30s.
Ciprofol+Esketamine group:Esketamine was administered intravenously at 0.2mg/kg, and then 0.4mg/kg Ciprofol was slowly injected 1min later for 30s.
Sponsors
The First Affiliated Hospital of Wenzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Age = 18 years old, = 75 years old, gender unlimited 2.Patients receiving conventional painless gastroscopy combined with colonoscopy for diagnosis and treatment 3.ASA rated as Level I or II 4.18kg/m2=BMI=30kg/m2 5.Expected gastroscopy operation time does not exceed 30 minutes 6.Clearly understand and voluntarily participate in the study, and have their informed consent form signed by themselves or their family members
Exclusion criteria
Exclusion criteria: 1.Complex endoscopic diagnosis and treatment techniques are required, with an estimated gastrointestinal endoscopy operation time exceeding 30 minutes 2.Long term use of opioid drugs 3.Patients planning to undergo tracheal intubation 4.After entering the room, the patient's SpO2 = 95% 5.Diagnosed as sleep apnea syndrome 6.Has serious heart disease 7.Systolic blood pressure = 180mmHg or/and diastolic blood pressure = 110mmHg 8.History of respiratory dysfunction and obstructive pulmonary disease 9.There is a history of uncontrolled diseases with significant clinical significance, such as liver, kidney, blood system, nervous system, or metabolic system, that researchers have determined may not be suitable for participation in the study 10.Pregnant or lactating women 11.Known allergies to eggs, soy products, opioid drugs and their antidotes, propofol, etc 12.Participated in other drug clinical trials as a subject within 3 months 13.Have a history of alcoholism within 3 months 14.Individuals with a history of traumatic brain injury, possible seizures, myoclonus, intracranial hypertension, cerebral aneurysm, or cerebrovascular accident; Patients with schizophrenia, intellectual disabilities, mania, mental disorders, long-term use of psychotropic drugs, drug addiction, and a history of cognitive impairment 15.Researchers believe that patients should not participate in this trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sedation success rate;Overall incidence of adverse events; | — |
Secondary
| Measure | Time frame |
|---|---|
| Wake-up time; | — |
Countries
China
Contacts
Public ContactWeijian Wang
The First Affiliated Hospital of Wenzhou Medical University
Outcome results
None listed